Skip to main content

Table 4 Comparisons of published meta-analyses

From: Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis

Study (Ref.) Included studies Summary of study conclusion Additional remarks
Adhikari et al.(2004) [9] Three RCTs Early high-dose corticosteroids had no effect on early mortality. Corticosteroids given for late phase ARDS reduced hospital mortality. Study interest not focused on corticosteroids; few studies and small sample size.
Agarwal et al. (2007) [10] Four RCTs and two cohort studies Current evidence does not support a role for corticosteroids in the management of ARDS in either the early or late stages of the disease. Excluding the RCTs of preventive use of corticosteroids; including high-dose corticosteroid study.
Peter et al. (2008) [11] Nine RCTs (eight RCTs for mortality analysis) A definitive role of corticosteroids in the treatment of ARDS in adults is not established. Including the RCTs of preventive use of corticosteroids; excluding pneumonia studies; using Bayesian random effects models for data pooling.
Tang et al. (2009) [12] Four RCTs (three ARDS studies and one pneumonia study) and five cohort studies The use of low-dose corticosteroids was associated with improved mortality and morbidity outcomes without increased adverse reactions. Including a RCT of pneumonia; excluding studies of high-dose and preventive use of corticosteroids.
Lamontagne et al. (2010) [13] Twelve RCTs (six ARDS studies and six pneumonia studies) Corticosteroids administered within 14 days of disease onset may reduce all-cause mortality. Including six studies of pneumonia.
  1. ARDS, acute respiratory distress syndrome; RCTs, randomized controlled trials.